A $5 million donation, then a Medicare crackdown on unproven wound bandages was shelved

In November 2024 CMS announced that from February 12, 2025 it would limit Medicare coverage of skin substitutes, wound dressings used mainly on diabetic foot and venous leg ulcers, to products supported by evidence of effectiveness. The agency identified seventeen products that had proven effective in scientifically valid studies. Extremity Care's products were not among them. Two of them, Coll-e-Derm and CompleteFT, were priced at $11,051.10 and $7,812.38 per square inch. Medicare spending in this category had risen from $256 million in 2019 to more than $10 billion in 2024, and by 2025 exceeded what the program spent on ambulance rides, anesthesia, or CT scans.

A blanket regulatory freeze pushed the rule to April 13, 2025. On February 24, Extremity Care gave $5 million to MAGA Inc., the president's principal super PAC. Six days later he attacked the rule publicly, asserting it would cause 431,429 lost limbs and 187,286 additional deaths each year, figures for which no support has been identified. On April 11, forty days after the post, CMS announced the rule would not take effect until at least January 1, 2026. The donation itself was not disclosed until July 31, when MAGA Inc. filed its ninety-six-page mid-year FEC report; the contribution appears on page 18. Between April and July, Medicare spent a further $2.3 billion on skin substitutes.

Two facts cut against reading the delay as a purchase. In July 2025 the same administration proposed a rule capping payment for skin substitutes at $806 per square inch, against an average price of $5,089, and the industry coalition that includes Extremity Care has lobbied against it, proposing a cap as high as $6,277.41. And no prosecutor has alleged, and no court has found, an exchange. What is documented is the sequence: a $5 million donation, a presidential attack six days later, an eight-month delay six weeks after that, and disclosure five months after the fact. In October 2025 Extremity Care's chief executive attended a donor dinner at the White House, and the company later gave a reported $2.5 million toward the ballroom project documented at GOV-04.

Documented; the donation appears in MAGA Inc.'s FEC mid-year report and the delay in CMS's own announcement. No quid pro quo has been alleged by any prosecutor or found by any court

No investigation, charge, or adjudication is on the public record. Donations to a super PAC are lawful and unlimited. The causal link between the donation and the delay is an inference from sequence, not a finding

$5 million to MAGA Inc. on Feb. 24, 2025, plus a reported $2.5 million toward the White House ballroom. Medicare spending on skin substitutes rose from $256 million in 2019 to more than $10 billion in 2024 and was projected to reach $15.4 billion by the end of 2025

Rule due to take effect 2025-02-12; delayed to 2025-04-13 by regulatory freeze; donation 2025-02-24; presidential post 2025-03-02; CMS delay to 2026-01-01 announced 2025-04-11; donation disclosed 2025-07-31